FDA Warns Consumers of Pro ArthMax Dangers

The Food and Drug Administration (FDA) is advising consumers not to purchase or use Pro ArthMax, a product promoted and sold as a dietary supplement for joint, muscle and arthritic pain.

FDA laboratory analysis confirmed that Pro ArthMax contains the active ingredients diclofenac, ibuprofen, naproxen, indomethacin, nefopam, and chlorzoxazone.

Mature doctor working on laptopDiclofenac, ibuprofen, naproxen, and indomethacin are non-steroidal anti-inflammatory drugs (NSAIDs). NSAIDs may cause increased risk of cardiovascular events, such as heart attack and stroke, as well as serious gastrointestinal damage including bleeding, ulceration, and fatal perforation of the stomach and intestines.

Chlorzoxazone is a muscle relaxant that is only available by prescription. Chlorzoxazone may cause drowsiness, dizziness, and lightheadedness, which may impair the ability to perform certain tasks, such as driving a motor vehicle or operating machinery.

Nefopam is a non-narcotic pain relieving drug that is not approved for marketing in the U.S. Because nefopam is not FDA-approved, safety or efficacy has not been established. In literature, adverse events such as, rapid heart rate, sweating, dizziness, confusion, hallucinations, and seizures have been reported with nefopam use.

Drug Interactions
These hidden drug ingredients may interact with other medications and significantly increase the risk of adverse events, particularly when consumers already may be using NSAID-containing products.

Consumers should stop using this product immediately and throw it away.
Consumers should consult a health care professional as soon as possible if they have experienced any negative side effects, such as unusually dark stools or urine, stomach pain, increased bruising, other signs of bleeding, confusion, sedation, hallucinations, and seizures.

Updated on: 08/18/16
Continue Reading
Physician Burnout and Professional Dissatisfaction Linked to Electronic Health Records and Computerized Physician Order Entry

Get new patient cases delivered to your inbox

Sign up for our healthcare professional eNewsletter, SpineMonitor.
Sign Up!